Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies

Brent R. Wright, Arthur E. Warrington, Dale E. Edberg, Moses Rodriguez

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Natural autoreactive monoclonal IgM antibodies have demonstrated potential as therapeutic agents for central nervous system (CNS) disease. These antibodies bind surface antigens on specific CNS cells, activating intracellular repair-promoting signals. IgM antibodies that bind to surface antigens on oligodendrocytes enhanced remyelination in animal models of multiple sclerosis. IgM antibodies that bind to neurons stimulate neurite outgrowth and prevent neuron apoptosis. The neuron-binding IgM antibodies may have utility in CNS axon- or neuron-damaging diseases, such as amyotrophic lateral sclerosis, stroke, spinal cord injury, or secondary progressive multiple sclerosis. Recombinant remyelination-promoting IgM antibodies have been generated for formal toxicology studies and, after Food and Drug Administration approval, a phase 1 clinical trial. Natural autoreactive monoclonal antibodies directed against CNS cells represent novel therapeutic molecules to induce repair of the nervous system.

Original languageEnglish (US)
Pages (from-to)1456-1459
Number of pages4
JournalArchives of Neurology
Volume66
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

Immunoglobulin M
Central Nervous System
Monoclonal Antibodies
Antibodies
Neurons
Surface Antigens
Chronic Progressive Multiple Sclerosis
Drug Approval
Clinical Trials, Phase I
Central Nervous System Diseases
Oligodendroglia
Amyotrophic Lateral Sclerosis
United States Food and Drug Administration
Spinal Cord Injuries
Toxicology
Nervous System
Multiple Sclerosis
Axons
Animal Models
Stroke

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies. / Wright, Brent R.; Warrington, Arthur E.; Edberg, Dale E.; Rodriguez, Moses.

In: Archives of Neurology, Vol. 66, No. 12, 12.2009, p. 1456-1459.

Research output: Contribution to journalArticle

Wright, Brent R. ; Warrington, Arthur E. ; Edberg, Dale E. ; Rodriguez, Moses. / Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies. In: Archives of Neurology. 2009 ; Vol. 66, No. 12. pp. 1456-1459.
@article{1789c39880e5487596f32f99111f78e1,
title = "Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies",
abstract = "Natural autoreactive monoclonal IgM antibodies have demonstrated potential as therapeutic agents for central nervous system (CNS) disease. These antibodies bind surface antigens on specific CNS cells, activating intracellular repair-promoting signals. IgM antibodies that bind to surface antigens on oligodendrocytes enhanced remyelination in animal models of multiple sclerosis. IgM antibodies that bind to neurons stimulate neurite outgrowth and prevent neuron apoptosis. The neuron-binding IgM antibodies may have utility in CNS axon- or neuron-damaging diseases, such as amyotrophic lateral sclerosis, stroke, spinal cord injury, or secondary progressive multiple sclerosis. Recombinant remyelination-promoting IgM antibodies have been generated for formal toxicology studies and, after Food and Drug Administration approval, a phase 1 clinical trial. Natural autoreactive monoclonal antibodies directed against CNS cells represent novel therapeutic molecules to induce repair of the nervous system.",
author = "Wright, {Brent R.} and Warrington, {Arthur E.} and Edberg, {Dale E.} and Moses Rodriguez",
year = "2009",
month = "12",
doi = "10.1001/archneurol.2009.262",
language = "English (US)",
volume = "66",
pages = "1456--1459",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies

AU - Wright, Brent R.

AU - Warrington, Arthur E.

AU - Edberg, Dale E.

AU - Rodriguez, Moses

PY - 2009/12

Y1 - 2009/12

N2 - Natural autoreactive monoclonal IgM antibodies have demonstrated potential as therapeutic agents for central nervous system (CNS) disease. These antibodies bind surface antigens on specific CNS cells, activating intracellular repair-promoting signals. IgM antibodies that bind to surface antigens on oligodendrocytes enhanced remyelination in animal models of multiple sclerosis. IgM antibodies that bind to neurons stimulate neurite outgrowth and prevent neuron apoptosis. The neuron-binding IgM antibodies may have utility in CNS axon- or neuron-damaging diseases, such as amyotrophic lateral sclerosis, stroke, spinal cord injury, or secondary progressive multiple sclerosis. Recombinant remyelination-promoting IgM antibodies have been generated for formal toxicology studies and, after Food and Drug Administration approval, a phase 1 clinical trial. Natural autoreactive monoclonal antibodies directed against CNS cells represent novel therapeutic molecules to induce repair of the nervous system.

AB - Natural autoreactive monoclonal IgM antibodies have demonstrated potential as therapeutic agents for central nervous system (CNS) disease. These antibodies bind surface antigens on specific CNS cells, activating intracellular repair-promoting signals. IgM antibodies that bind to surface antigens on oligodendrocytes enhanced remyelination in animal models of multiple sclerosis. IgM antibodies that bind to neurons stimulate neurite outgrowth and prevent neuron apoptosis. The neuron-binding IgM antibodies may have utility in CNS axon- or neuron-damaging diseases, such as amyotrophic lateral sclerosis, stroke, spinal cord injury, or secondary progressive multiple sclerosis. Recombinant remyelination-promoting IgM antibodies have been generated for formal toxicology studies and, after Food and Drug Administration approval, a phase 1 clinical trial. Natural autoreactive monoclonal antibodies directed against CNS cells represent novel therapeutic molecules to induce repair of the nervous system.

UR - http://www.scopus.com/inward/record.url?scp=73549115379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73549115379&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2009.262

DO - 10.1001/archneurol.2009.262

M3 - Article

VL - 66

SP - 1456

EP - 1459

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 12

ER -